Form 4: ImmuCell CFO Acquires 30,000 Incentive Stock Options
SEC Form 4
Timothy C. Fiori, CFO of ImmuCell Corp, reports the acquisition of 30,000 incentive stock options.
Summary
- On April 16, 2025, Timothy C. Fiori, the Chief Financial Officer of ImmuCell Corp, acquired 30,000 incentive stock options.
- The options have an exercise price of $5.49.
- The options are exercisable from April 16, 2028, and expire on April 16, 2035.
- Following the transaction, Fiori directly owns 30,000 derivative securities.
Sentiment
Score: 5
Explanation: This is a routine disclosure of stock option grants, neither particularly positive nor negative.
Industry Context
This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities. It is common for company executives to receive stock options as part of their compensation.
Stakeholder Impact
- The granting of stock options to the CFO aligns his interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 04/16/2025 | Date of transaction: CFO acquired 30,000 incentive stock options. |
| 04/16/2028 | Options become exercisable. |
| 04/16/2035 | Options expire. |
| 04/23/2025 | Date of signature on the Form 4 filing. |
Keywords
ImmuCell Corp, ICCC, Form 4, Incentive Stock Options, CFO, Timothy C. Fiori, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.